sequencing-based diagnostics

The in vitro diagnostic test runs on the Illumina NovaSeq 6000 instrument and will be performed at Helix's San Diego CLIA-certified laboratory.

NantHealth's net loss more than tripled in the second quarter, though it continues to build up its cash reserves.

The San Diego-based genomic analysis firm said the decline in revenues was due to the impact of the COVID-19 pandemic on research customers.

The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.

The genetic testing company said its orders for traditional tests have also rebounded and are on track for growth in the second half of 2020.

Asuragen will develop assays for PacBio's long-read next-generation sequencing systems, with an initial focus on developing a carrier screening assay.

The targeted sequencing assay analyzes 12 genes and can be paired with the firm's BRCA gene testing kit.

The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.